Nurexone Biologic Inc. logo

Nurexone Biologic Inc. (NRX)

Market Closed
28 May, 20:00
NEO-L NEO-L
CA$
0. 6400
+0.08
+14.29%
CA$
- Market Cap
- P/E Ratio
- Div Yield
10,000 Volume
- Eps
CA$ 0.56
Previous Close
Add Transaction
Day Range
0.64 0.64
Year Range
0.56 1.08
Want to track NRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NRX closed Thursday higher at CA$0.64, an increase of 14.29% from Wednesday's close, completing a monthly increase of 10.34% or CA$0.06. Over the past 12 months, NRX stock gained 0%.
NRX is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XSTU (EUR).

NRX Chart

Nurexone Biologic Inc. (NRX) FAQ

What is the stock price today?

The current price is CA$0.6400.

On which exchange is it traded?

Nurexone Biologic Inc. is listed on NEO-L.

What is its stock symbol?

The ticker symbol is NRX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Nurexone Biologic Inc. ever had a stock split?

No, there has never been a stock split.

Nurexone Biologic Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Yoram Drucker CEO
NEO-L Exchange
- ISIN
CA Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

NurExone Biologic Inc. is a distinguished pharmaceutical technology company, launched in 2020, and situated in Toronto, Canada. The firm is at the forefront of innovation with its focus on developing groundbreaking treatments for some of the most challenging medical conditions. By leveraging cutting-edge membrane-bound extracellular vesicles technology, NurExone Biologic Inc. is committed to transforming the landscape of treatments for spinal cord injuries, brain trauma, and various neurological disorders. This technology paves the way for off-the-shelf, non-invasive solutions, offering new hope for illnesses that have long been considered untreatable or difficult to manage.

Products and Services

At NurExone Biologic Inc., our product development pipeline is specifically designed to address several critical areas within the realm of neurological health and recovery. Our innovative approach to treatment is built around the potent potential of membrane-bound extracellular vesicles technology. Here's a closer look at our primary focus areas:

  • Spinal Cord Injury Treatment: We are developing an off-the-shelf, non-invasive treatment that aims to reverse or significantly reduce paralysis resulting from spinal cord injuries. This groundbreaking approach holds the promise of drastically improving the quality of life for patients suffering from spinal cord injuries, offering them a chance at recovery beyond traditional rehabilitation methods.
  • Brain Trauma Treatment: Our research and development efforts extend to creating novel treatments for brain trauma injury. By focusing on non-invasive methodologies, we strive to mitigate the impacts of brain trauma and accelerate the recovery process, thereby reducing the long-term consequences and improving outcomes for victims of traumatic brain injuries.
  • Treatment for Other Brain and Neurological Indications: The flexible and robust nature of our proprietary technology enables us to explore treatments for a broader spectrum of brain and neurological conditions. This includes but is not limited to, diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Our aim is to unveil treatment options that can halt or reverse the progression of these debilitating conditions, thereby enhancing the overall well-being and functionality of affected individuals.

Contact Information

Address: 1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9
Phone: -